48 results
S-4/A
NGNE
Neurogene Inc
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
. Treatment-emergent adverse events could also affect patient recruitment or the ability of enrolled subjects to complete its clinical trials or could … recruitment and retention efforts.
Neurogene’s future growth may depend, in part, on its ability to operate in foreign markets, where it would
S-4
adebtiv3h17z0bklfr
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm